Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

(2011) Thorsten Simon et al.   BMC CANCER

Comparison of 123I-metaiodobenzylguanidine (MIBG) and 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group

(2011) Arlene Naranjo et al.   PEDIATRIC BLOOD & CANCER

Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project

(2011) Hervé J. Brisse et al.   RADIOLOGY

Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

(2010) K K Matthay et al.   BRITISH JOURNAL OF CANCER

Epidemiology of childhood cancer

(2010) Peter Kaatsch   CANCER TREATMENT REVIEWS

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97

(2008) Matthias Schmidt et al.   EUROPEAN JOURNAL OF CANCER

Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97

(2008) Barbara Hero et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY